ArticleJournal of musculoskeletal & neuronal interactions2023
Mechanism of miRNA-31 Regulating Wnt/β-catenin Signaling Pathway by Targeting Satb2 in the Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells.
Article in Journal of musculoskeletal & neuronal interactions, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 3 citations in OpenAlex.
- Astragaloside IV inhibits nasopharyngeal carcinoma progression by inhibiting SATB2/Wnt/PD-L1 pathway and enhancing the killing activity of T cells.European journal of histochemistry : EJH · 2026Article
- Association between lncRNA H19 and osteoporosis in postmenopausal patients with type 2 diabetes mellitus.Journal of orthopaedic surgery and research · 2025Article
- Advances in research on SATB2 and its role in tumor development.Cell & bioscience · 2025Review
- Astragaloside IV inhibits nasopharyngeal carcinoma progression by suppressing the SATB2/Wnt signaling axis.Toxicology research · 2025Article
- The Cross Talk of MicroRNAs and SATB2 Signaling Pathway in Osteogenesis in the Context of Dental Implants.International journal of molecular and cellular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the expression of miR-31 and Satb2 gene in the serum of postmenopausal women with osteoporosis (OP).
methods97 postmenopausal women with OP and 100 healthy women were selected as research subjects. MSCs were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. Bone marrow-derived mesenchymal stem cells (BMSCs) were isolated, identified and transfected, and then quantified by alkaline phosphatase (ALP) levels. The expression levels of miR-31 and Satb2 gene mRNA were determined by qRT-PCR. The proteins of RUNX2, OCN and BMP and Wnt/β-catenin pathway-related proteins (GSK-3, Frizzled 1, Lrp5, Lrp6 and β-catenin) were tested by Western blotting.
resultsIn the OP group, the relative expression of miR-31 was 3.61±0.54, significantly higher than that (1.75±0.27) in the healthy control group (t=9.422, P<0.001). The relative expression of mRNA of Satb2 gene was 0.86±0.12, significantly lower than that (1.35±0.21) in the healthy control group (t=5.897, P<0.001).
conclusionsThe increase in miR-31 expression can down-regulate the Wnt/β-catenin pathway by targeting the expression of Satb2 gene, thereby inhibiting the osteogenic differentiation of BMSCs. This provides an important reference for further understanding the mechanism of OP and identifying targets for early diagnosis and treatment.
Indexed as
Identifiers
37654220PMC10483816W4386346658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.